Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Renal Pharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1446774

An Investigation into the Correlation between Intraperitoneal Teicoplanin concentrations and Treatment Outcomes in Peritoneal Dialysis-associated Peritonitis

Provisionally accepted
Lulu Wang Lulu Wang 1Jiangqing Fan Jiangqing Fan 2*Xuejie Chen Xuejie Chen 3Wenpu Lei Wenpu Lei 2*Chunming Jiang Chunming Jiang 3*Hang Liu Hang Liu 1*Yun Yang Yun Yang 4*Jizhong Shen Jizhong Shen 1*
  • 1 Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
  • 2 Department of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
  • 3 Department of Nephrology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China
  • 4 Department of Stomatology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nangjing University, Nangjing, China

The final, formatted version of the article will be published soon.

    Peritoneal dialysis-associated peritonitis (PDAP) is a frequent complication of peritoneal dialysis. The guidelines from the International Society for Peritoneal Dialysis (ISPD) suggest administering teicoplanin through the peritoneal route to treat PDAP, but do not specify the ideal concentration for peritoneal dialysis effluent (PDE). Patients meeting the trial criteria for PDAP in our hospital between July 2022 and December 2023 were enrolled. Data on PDE white blood cell count, PDE neutrophil percentage, clinical symptoms, CRP, and PCT were gathered pre-and post-treatment. Incidences of ADR and case numbers during treatment were recorded. Subsequently, PDAP patients who use intraperitoneal teicoplanin could effectively control infection by considering the PDE teicoplanin concentration (> 15.138 mg/L) on day 5 after dosing.

    Keywords: Peritoneal dialysis-associated peritonitis, Teicoplanin, Peritoneal dialysis effluent, Therapeutic drug monitoring, Individualized drug therapy

    Received: 10 Jun 2024; Accepted: 29 Aug 2024.

    Copyright: © 2024 Wang, Fan, Chen, Lei, Jiang, Liu, Yang and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jiangqing Fan, Department of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
    Wenpu Lei, Department of Pharmacy, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China
    Chunming Jiang, Department of Nephrology, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China
    Hang Liu, Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
    Yun Yang, Department of Stomatology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nangjing University, Nangjing, China
    Jizhong Shen, Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.